Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory

dc.authorid0000-0003-0052-1060
dc.contributor.authorCandan, Elif
dc.contributor.authorÜlker, Zeynep
dc.date.accessioned2026-11-19T07:14:30Z
dc.date.available2026-11-19T07:14:30Z
dc.date.issued2026
dc.departmentFakülteler, Diş Hekimliği Fakültesi, Temel Bilimler Bölümü
dc.description.abstractBackground Dietary flavonoids have been proposed as partners for platinum chemotherapy, but their effects vary between tumour types, and sparing of normal cells has to be demonstrated. We examined gossypetin and luteolin, alone and combined with cisplatin, in MCF-7 breast and HeLa cervical carcinoma cells and in non-tumorigenic L929 fibroblasts. Methods and Results Cells were exposed to 100 µg/mL cisplatin (CP), gossypetin (GOS), luteolin (LUT) or their double and triple combinations. Viability was measured by MTT assay (technical triplicates, one experiment), combination effects by Bliss independence, Bax, Bcl-2 and CASP3 transcripts by RT-PCR (2−ΔΔCt), and phosphatidylserine exposure by Annexin V–Cy3 staining of archived micrographs. At 48 h, six of the seven treatments reduced MCF-7 viability (61.8–85.0% of control; Tukey-adjusted p≤0.018), gossypetin being the most active. Cisplatin plus luteolin exceeded the Bliss expectation in MCF-7 at 24 h (excess+0.11), whereas all combinations were less than additive at 48 h. No treatment reduced HeLa viability, and HeLa cells showed Bcl-2 induction (1.9–30.2-fold) with Bax repression (Bax/Bcl-2 ratio 0.03–0.21). L929 viability was not reduced at either time point, and the archived L929 field showed no Annexin V labelling. Conclusions At this single concentration, gossypetin- and luteolin-based treatments reduced MCF-7 viability without reducing L929 viability, while HeLa cells were refractory at the viability and transcript levels. These retrospective data support dose–response and protein-level studies rather than mechanistic conclusions.
dc.identifier.citationCandan, E., & Ülker, Z. (2026). Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory. Molecular Biology Reports, 53(1), Article 1898.
dc.identifier.doi10.1007/s11033-026-13052-7
dc.identifier.issn0301-4851
dc.identifier.issue1
dc.identifier.pmid42980935
dc.identifier.scopus2-s2.0-105055873302
dc.identifier.urihttps://hdl.handle.net/20.500.12941/490
dc.identifier.volume53
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÜlker, Zeynep
dc.institutionauthorid0000-0003-0052-1060
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofMolecular Biology Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGossypetin
dc.subjectLuteolin
dc.subjectCisplatin
dc.subjectBreast Cancer
dc.subjectBax/Bcl-2
dc.subjectDrug Combination
dc.titleGossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory.pdf
Boyut:
5.39 MB
Biçim:
Adobe Portable Document Format
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: